Today's Special on the Anticancer Menu: Immunomodulation by Antifolates.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31562205.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2775.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pemetrexed is widely employed for the clinical management of mesothelioma and non-small cell lung carcinoma, largely based on its ability to curtail folate metabolism in highly proliferating cells. Recent preclinical findings suggest that the therapeutic efficacy of pemetrexed may involve an unsuspected immunologic component.<i>See related article by Schaer et al., p. 7175</i>.
Medical subject headings
- Folic Acid Antagonists
- Lung Neoplasms
- Mesothelioma